

Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.

Size
Quantity
Bundle & Save
Restock alert
Notify me when it’s back
Quality & methods
Reviews
Reviews reflect individual research observations only. All products are for research use only — not for human consumption.
No reviews yet. Be the first to share your research observations.
Purchased this? Leave a review from your account.
Type
Synthetic peptide (acylated, 44 residues)
Molecular formula
C221H366N72O67S
Molecular weight
~5,136 g/mol
CAS number
218949-48-5
Amino acids
44
Modification
Full GHRH(1-44) with an N-terminal trans-3-hexenoyl group; C-terminal amide.
A stabilized analogue of human GHRH(1-44) that binds the GHRH receptor (GHRHR), a class B GPCR. The N-terminal trans-3-hexenoyl group distinguishes it from native GHRH.
Lyophilized
20°C (-80°C extended)
typically stable 24-36 months desiccated.
Avoid freeze-thaw; aliquot; protect from light and moisture. Contains an oxidation-sensitive methionine.
Reviews
Spooner LM. (2012). Ann Pharmacother — Pharmacology and clinical-literature review (HIV-associated lipodystrophy population)
Dhillon S. (2011). Drugs — Clinical-program review (HIV-associated lipodystrophy population)
Reviews
Tomlinson B, Hu M. (2006). Expert Opin Investig Drugs — Early investigational-profile review
Bedimo R. (2011). HIV AIDS (Auckl) — Narrative review: GH axis and HIV-associated lipodystrophy management
Clinical
Ellis RJ, et al. (2025). J Infect Dis — Neurocognitive-endpoint study, HIV with abdominal obesity
Russo SC, et al. (2024). AIDS — Central-adiposity RCT, contemporary-ART HIV population
Fourman LT, et al. (2020). JCI Insight — Hepatic-transcriptomic-signature substudy, HIV-associated NAFLD
Stanley TL, et al. (2019). Lancet HIV — Liver-fat-endpoint RCT, HIV-associated NAFLD
Clemmons DR, et al. (2017). PLOS ONE — Glycemic and metabolic-endpoint RCT, type 2 diabetes population
Stanley TL, et al. (2014). JAMA — Visceral-fat and liver-fat-endpoint RCT, HIV with abdominal fat
Friedman SD, et al. (2013). JAMA Neurol — Brain-GABA neuroimaging study, mild cognitive impairment / healthy aging
Baker LD, et al. (2012). Arch Neurol — Cognitive-endpoint controlled trial, older adults
Makimura H, et al. (2012). J Clin Endocrinol Metab — Metabolic-endpoint RCT, obesity with reduced GH secretion
Stanley TL, et al. (2012). Clin Infect Dis — Secondary analysis of visceral-fat change vs metabolic markers, HIV population
Falutz J, et al. (2010). J Clin Endocrinol Metab — Pooled abdominal-adiposity analysis, HIV population
Falutz J, et al. (2010). J Acquir Immune Defic Syndr — Abdominal-fat-endpoint RCT and extension, HIV population
Falutz J, et al. (2008). AIDS — Long-term metabolic and safety extension, HIV population
Falutz J, et al. (2007). NEJM — Pivotal RCT of visceral-adiposity and metabolic endpoints, HIV population
Falutz J, et al. (2005). AIDS — Earliest randomized study, HIV population
Primary research
Stanley TL, et al. (2011). J Clin Endocrinol Metab — GH pulsatility and insulin-sensitivity study, healthy men
González-Sales M, et al. (2015). Clin Pharmacokinet — Population PK modeling, HIV-infected patients and healthy subjects
González-Sales M, et al. (2015). J Pharmacokinet Pharmacodyn — Population PK/PD modeling (GH and IGF-1 endpoints), HIV-infected patients